Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 11:50 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 265–288 of 308 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: lipitor Clear all

Conditions: Coronary Disease
Interventions: Placebo Oral Tablet, Atorvastatin 80mg, Screening; Drug · Other
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 97 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cognitive Impairment, Mild, Dementia, Cardiovascular Diseases
Interventions: Atorvastatin 40 Mg Oral Tablet, Placebo oral tablet; Drug
Lead sponsor: Duke University; Other
Eligibility: 75 Years and older
Enrollment: 20,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2026
U.S. locations: 104
States / cities: Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 70 more

Conditions: Diabetes Mellitus, Insulin-Dependent, Hypercholesterolemia
Interventions: Atorvastatin, Atorvastatin Placebo; Drug
Lead sponsor: Nemours Children's Clinic; Other
Eligibility: 10 Years to 20 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2014
U.S. locations: 5
States / cities: Wilmington, Delaware • Jacksonville, Florida • Orlando, Florida + 2 more

Conditions: Atrial Fibrillation, Inflammation
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 3
States / cities: Atlanta, Georgia

Conditions: Type 1 Diabetes
Interventions: Atorvastatin, Placebo; Drug · Other
Lead sponsor: Children's Hospital of Philadelphia; Other
Eligibility: 10 Years to 19 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Mixed Dyslipidemia
Interventions: ABT-335, rosuvastatin calcium, simvastatin, atorvastatin calcium; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Vascular Diseases
Interventions: Placebo, BMS-582949, Atorvastatin, Statin; Other · Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 17
States / cities: Chiefland, Florida • Jacksonville, Florida • Tampa, Florida + 13 more

Conditions: Hepatitis C
Interventions: 20 mg of atorvastatin daily; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 30 Years to 80 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Cardiothoracic Surgery, Post-operative Atrial Fibrillation
Interventions: Atorvastatin 20 mg, Atorvastatin 80 mg; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Coronary Artery Disease
Interventions: standard of care lipid therapy, Aggressive lipid therapy; Drug
Lead sponsor: Annapoorna Kini; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Influenza
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 116 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: NASH - Nonalcoholic Steatohepatitis
Interventions: Atorvastatin, Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 70 Years
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 2
States / cities: Rochester, Minnesota • Durham, North Carolina

Conditions: Heart Failure
Interventions: Placebo, Atorvastatin; Drug
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2023
U.S. locations: 3
States / cities: Boston, Massachusetts • Philadelphia, Pennsylvania

Conditions: Hypertriglyceridemia
Interventions: AMR101 (ethyl icosapentate) - 4 g/day, AMR101 (ethyl icosapentate) - 2 g/day, Placebo; Drug
Lead sponsor: Amarin Pharma Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 702 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 80
States / cities: Muscle Shoals, Alabama • Scottsboro, Alabama • Phoenix, Arizona + 69 more

Conditions: Hyperlipidemia, Dyslipidemia, Hypercholesterolemia
Interventions: torcetrapib/atorvastatin, simvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 640 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006
U.S. locations: 51
States / cities: Birmingham, Alabama • Mesa, Arizona • Alhambra, California + 48 more

Conditions: Mixed Dyslipidemia, Coronary Heart Disease, Dyslipidemia
Interventions: ABT-335, Atorvastatin, Placebo; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 613 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: North Chicago, Illinois

Conditions: Dyslipidemia
Interventions: LCP-AtorFen, atorvastatin, fenofibrate; Drug
Lead sponsor: Asahi Kasei Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atypical Ductal Breast Hyperplasia, Breast Cancer, Ductal Breast Carcinoma in Situ, Lobular Breast Carcinoma in Situ
Interventions: atorvastatin calcium, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 72 Years · Female only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK2248761, Simvastatin, Atorvastatin, Rosuvastatin; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010
U.S. locations: 1
States / cities: Austin, Texas

Conditions: End-Stage Kidney Disease
Interventions: Atorvastatin (Lipitor); Drug
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hyperlipidemia
Interventions: Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin; Biological · Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 2,067 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 65
States / cities: Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more

Conditions: Abortion Early
Interventions: Atorvastatin, Misoprostol; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Dyslipidemia, Hypertension
Interventions: Amlodipine besylate, Amlodipine besylate/atorvastatin calcium single pill combination; Drug
Lead sponsor: Pfizer's Upjohn has merged with Mylan to form Viatris Inc.; Industry
Eligibility: 21 Years and older
Enrollment: 245 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 51
States / cities: Birmingham, Alabama • Mesa, Arizona • Garden Grove, California + 44 more

Conditions: Healthy
Interventions: Atorvastatin; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Fargo, North Dakota

Search by objective public record fields.

Effects of Atorvastatin on Myonecrosis

Pragmatic Evaluation of Events And Benefits of Lipid-lowering in Older Adults

Statins in Children With Type 1 Diabetes and Hypercholesterolemia

Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Atorvastatin in New Onset Type 1 Diabetes Mellitus (T1DM)

A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed Dyslipidemia

Efficacy Study of p38 Kinase Inhibitor to Treat Patients With Atherosclerosis

Assessment of the Antiviral Effect of Atorvastatin on Hepatitis C Virus

Intensive Statin Therapy Effect on Post-Operative Atrial Fibrillation (POAF)

Reduction in YEllow Plaque by Aggressive Lipid LOWering Therapy

Statin Therapy in Acute Influenza

Statins for the Treatment of NASH

STOP-CA (Statins TO Prevent the Cardiotoxicity From Anthracyclines)

Effect of AMR101 (Ethyl Icosapentate) on Triglyceride (Tg) Levels in Patients on Statins With High Tg Levels (≥ 200 and < 500 mg/dL)

A Clinical Trial Comparing Torcetrapib/Atorvastatin To Simvastatin In Subjects With High Cholesterol (A5091031).

Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the Blood

Study of Atorvastatin/Fenofibrate (LCP-AtorFen) Combination Therapy in Dyslipidemia

A Phase I Prevention Study of Atorvastatin in Women at Increased Risk for Breast Cancer

A Drug Interaction Study Between Simvastatin, Atorvastatin, Rosuvastatin, and GSK2248761 in Healthy Subjects.

Use of Atorvastatin (Lipitor) to Decrease Panel Reactive Antibody Titers

LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2

Atorvastatin as a Potential Adjunct to Misoprostol for Termination of Pregnancy

A Multi-Risk Factor Strategy vs a Guideline-Based Approach in Achieving Blood Pressure and Lipid Goals in Hypertensives at Extra Risk

A Bioequivalence Study Of 80 Mg Atorvastatin Calcium Tablets Versus 80 Mg Lipitor® Tablets Under Fasting Conditions.